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Vision’ary: Drug Delivery for Ocular Diseases
Amber Sarver1,2*, Sam Goddard2, Jennifer Tournear2, Dr. Elizabeth Gaillard1,2
Northern Illinois University, Dept. of Chemistry and Biochemistry1; Northern Illinois University, Dept. of
Biology2

Abstract Retinal ocular diseases such as age-related macular degeneration (AMD), clinically significant diabetic macular edema
(DME), diabetic retinopathy (DR) and retinal vein occlusions are currently difficult to treat effectively with topical medications
and eye drops. Intravitreal injections of pharmacological products are currently the most effective method of treatment. Frequent
injections have been found to have adverse effects including infection, endophthalmitis and retinal detachment. Inconsistent
patient compliance decreases the effectiveness of the pharmaceuticals and the fiscal impact also poses a problem with recurring
intravitreal injections. Liposomes are nano-sized bi-layered vesicles that will encapsulate various hydrophilic or hydrophobic
substances necessary for treatment of ocular diseases. Liposomes can be formulated to slowly release the drug thereby preventing
frequent painful injections. Liposomes of various lipid to cholesterol concentrations were formulated using the ethanol-injection
method and then extruded with a 100 nm pore sized polycarbonate filter. The liposomes were then characterized via confocal
microscopy, dynamic light scattering, and transmission electron microscopy to analyze size, homogeneity, stability, and
encapsulation efficiency.

I. INTRODUCTION1

T

HERE are many barriers encountered when
attempting ocular drug delivery to the retina. Drugs
cannot be easily delivered to the retina by topical methods
like eye drops because of structural barriers including the
cornea and the lens. Figure 1 shows the anatomy of the eye
illustrating the retina, the light sensitive layer of the eye. A
localized portion of the retina is the macula, encasing the
rods and cones, allowing sight in both the dark and in the
light. Systemically administered drugs seldom enter the
retina because of the blood/aqueous barrier and the
inner/outer blood retinal barriers, consisting of retinal
capillary endothelial cells and retinal pigment epithelium
cells (RPE), therefore leaving intravitreal injection the
current preferred method. 1

Fig. 1 Anatomy of the eye 3
Current drug delivery options include eye drops,
intravitreal injections and liposomes. Eye drops that are
administered for acute ocular diseases are often
inconsistent in the effectiveness and can cause dry eye
and allergic conjunctivitis. It has been reported that 80%
of the drops administered exit the eye via the lacrimal
duct after two minutes and only 5% of the free drug
enters after tearing.1,2
Musin, produced by the tears, forms a hydrophilic
barrier around the outer layer of the eye preventing
foreign particles from adhering and entering the topical
layers.4 The exterior of the eye is split into the epithelium,
stroma, and endothelium.5 Figure 2 highlights the
individual layers of the cornea.6 The exterior stroma and
epithelium of the cornea and conjunctiva form a blockade
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preventing diffusion of most drugs.4 Tight cell junctions,
lipophilicity and pKa are the determining factors in what
can and cannot enter the cornea.1,7

Fig. 3 Injection through the pars plana of eye 14

Fig. 2 Layers of the cornea 6
Intravitreal injection of pharmaceuticals have recently
been used for the treatment of several ocular diseases
including age-related macular degeneration (AMD),
clinically significant diabetic macular edema (DME),
diabetic retinopathy (DR) and retinal vein occlusions. These
ocular diseases dramatically influence the quality of life of
more than 8 million people worldwide.4 The major ocular
disorders of Americans forty years or older create a fiscal
impact of $35.4 billion.8
Injections, in the form of solutions, particulates, or
suspensions, targeted at the retina must pierce the pars plana
(Fig. 3). The benefits of these intravitreal injections include
transcending issues from eye drops, allowing direct contact
with the posterior eye, and reducing systemic effects caused
by oral medications.9 Many risk factors are associated with
intravitreal injections including: infection of the ocular
surface, infection caused by contaminated surgical
equipment or pathogens, pain, swelling, increased ocular
pressure and retinal detachment.2,10 The viscosity of the
drug being administered may convolute the natural vitreous
humor, containing collagen and hyaluronic acid inside the
eye cavity, causing localized complications and decreased
vision.4,10,11 If the solution injected is more dense than water
it may fall to the bottom of the eye due to gravity, ceasing to
be therapeutic.12 The negative overall charge of the vitreous,
due to the hyaluronic acid, induces positive particles to
aggregate within the eye making the charge extremely
important in respect to the injection of medications.4 The
mode of intravitreal injection into the eye is via a 27-30
gauge syringe.13 It should be noted that the volume of the
aqueous humor in the eye is approximately 1 milliliter so
the amount of solution injected as well as the concentration
is important.5

Free drugs administered intraocularly tend to have short
half-lives and frequent injections are necessary for
satisfactory treatment.9, 15 This half-life is dependent upon
the route that the drug takes once inside the aqueous humor,
the jelly-like solution inside the eye cavity. The drug may
be diffused into the aqueous humor and eliminated via its
rejuvenation or the blood. It may also cross the blood/brain
barrier due to permeability or a transport protein. 4
AMD can be subdivided into wet and dry. Dry AMD is
categorized by the formation of a defined, vascular, circular
area forming on the retina with a pale color due to
diminished pigment. Patients have a loss of vision in a
localized area. The wet form is indicative of a fluid layer
forming in the Bruch’s membrane and causing the RPE cells
to detach. This interference with the photo receptors induces
blurry vision called metamorphopsia and may lead to
permanent blindness.16
The liposomal preparation for our studies focuses on the
disease process of wet AMD. For decades the treatment of
ocular diseases via intravitreal injection has been used to
administer steroids for the treatment of AMD.13 This
particular ocular disease affects central vision and is caused
by a deterioration of the photoreceptors in the macula. The
first signs of AMD are hyper or hypo pigmentation of the
RPE cells.8 A build-up of drusen underneath the RPE cells
creates a layer of fragmented lipids, cellular components,
vitamin A by-products and proteins. The pathogenesis of
the disease is not currenty understood, but many theories
have been postulated including damage by oxidation, nonfunctioning RPE or Bruch’s membrane, increased apoptosis,
immune response, or lipofuscin aggregation.8 There is now
contention that the two forms of AMD, wet and dry, are two
different disease processes.
Repetitive injections lead to decreased patient
compliance and substantial increase in cost. Placement of
these drugs in capsulated particles increases the duration of
effectiveness of these drugs by 3-6 months thus decreasing
the frequency of injections.9
There are currently no FDA approved long term delivery
options available for treatment to the anterior portion of the
eye.1
A more direct application of ocular medications is needed
in order for the performance of the drugs to be significantly
effective and a long-term release process to decrease risk of

5
patient compliance, decrease cost, and risk of infection.
The solution to these aforementioned problems may lie in
the treatment of ocular diseases with liposomes. Liposomes
are spherical vesicles made up of a lipid bi-layered
membrane that plays an important role in the encapsulation
of drugs in particular but also can enclose proteins,
enzymes, antibiotics, hormones and viruses.2, 18 A
hydrophobic layer lies within the nonpolar tails of the
bilayer where hydrophobic drugs can be positioned and a
hydrophilic core where hydrophilic drugs can be contained,
allowing the liposome to have an ampiphillic quality.11, 18
There exist various lipid compositions both in nature and
bioengineered liposomes. Phosphotidylcholine (PC), Fig. 4,
has been found to be a viable lipid used in the formation of
liposomes. This lipid is the makeup of many biological
membranes and is important in cell membrane signaling.19 It
is the most abundant phospholipid in animals, plants and
can be found in egg yolk.20 Because of its cylindrical shape,
PC spontaneously forms a bilayer so it is ideally suited for
the bulk of the plasma membrane or, in this case, the
liposome bilayer.11 This molecule contains a choline polar
head group with hydrocarbon non-polar tails and is
categorized as a glycerophospholipid.21 The unsaturated
acyl chains are linked and confer fluidity on the membrane.
The amphipathic bilayer not only surrounds the hydrophilic
core where hydrophilic drugs can be contained, but
hydrophobic drugs can also be dissolved in between the
non-polar bilayer.2

Fig. 4 Structure of Phosphatidylcholine 21
To prevent the liposome from being too fluid, prevent
leakage and reduce permeability, cholesterol (CH) can be
added to the liposome formulation, filling in the free space
between the lipids.22, 23 The molecular structure of
cholesterol is depicted in Fig. 5. The body of cholesterol
consists of a series of fused rings that make the molecule
quite rigid. At one end of this planar ring system is a
hydroxyl group and at the other end is a hydrocarbon tail, so
cholesterol, like other membrane lipids, has both
hydrophilic and hydrophobic poles that determine its
positioning within the lipid bilayer.21 When the hydroxyl
group is next to the phospholipid ester carbonyl, the rigid
body of cholesterol is situated alongside the fatty-acid tails
of neighboring phospholipids and can help to order these
tails (Fig. 6).

Fig. 5 Structure of Cholesterol 21

Fig. 6 Positioning of cholesterol in a bi-layered
membrane 21
The main parameters of our liposomes are slow release
and stability. We want to utilize them as a slow release
vesicle. Encapsulation stability and entrapment is extremely
important in our formulations. The quality must be
maintained so no leaking occurs of the drug prematurely.
Encapsulation prevents the drug from interacting with
surrounding molecules and being metabolized by enzymes
and thereby reducing the drug’s effectiveness.18
The actual manufacturing method and preparation also
needs to be taken into account when thinking wide scale
production. Proper materials need to be used to prevent any
cytotoxicity and cell death to the fragile tissues of the eye.15
Systemic affects also need to be considered when
administering any form of the drug. 23
Liposomes are also currently being researched and
developed for the treatment of cancer and respiratory
diseases by adding polyethylene glycol (PEG) to the
liposome formulation to improve encapsulation efficiency
and to attach PEG conjugates for specific binding and
uptake by the target cell.15, 24 PEG liposomes are also
proven to prevent fusion and aggregation.25 Studies are also
in effect to deliver encapsulated drugs via eye drops
although no substantial evidence is confirmed that
liposomes can penetrate the outer surface.7, 26
Size plays an important role in the preparation of
liposomes. Liposomes must be in the nano-size range to be
a potential drug carrier targeting the retina.18 The larger the
particle, the more light scattering will occur, interfering with
vision.11 Nanoparticles up to 500 nanometers in diameter
that bypass the possible obstruction of steric hindrance in
the vitreous humor, having no PEG attachments have been
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found to be distributed quickly through the internal eye.
Particles larger than 500 nanometers can interact with the
vitreous and remain in the gelatin like material, never
reaching the retina.9 An advantage of liposomes without
PEG attachments eliminates the need for covalent
interactions which may decrease the activity of the
PEGylated molecule.11
The surface area of each particle is very large compared
to the volume and the size making them more soluble.
Therefore the drug can dissolve more readily and become
bioavailable in the body. They also need to have the ability
to hold a homogeneous liposome size that are stable and can
hold their encapsulated payload.4 These are the primary key
elements to be studied for an effective liposome carrier.
Due to the size of small uni-lamellar vesicle (SUV, 20-50
nanometers) or large uni-lamellar vesicle (LUV, 100
nanometers), direct uptake by the eye has been shown
ineffective. Studies state that SUV have a shorter half-life
than LUV.20
In order to determine optimal release stability we
formulated and produced liposomes with various lipid to
cholesterol molar ratios and formed liposomes via ethanolinjection method and extrusion to observe the resulting
stability, size, aggregation, and encapsulation efficiency via
transmission electron microscopy (TEM), confocal
microscopy (CM), and dynamic light scatterer (DLS).

magnetic stir plate. The argon gas was an attempt to remove
any cytotoxic solvent that would be damaging to the eye.
The liposomes were then extruded using an extruder with
nitrogen gas 10 times through a .4 µm polycarbonate filter,
10 times with a .2 µm filter and 10 times with a .1 µm filter
using aseptic technique.
C. Characterization of liposomes
Each sample was then diluted to 10 mM in order to
characterize using fluorescence microscopy (Fig. 7). The
liposomes were then viewed using UV (Fig. 8). The TEM
(Fig. 9) was used to view the liposomes and note any
aggregation or large size differential. Images of the
liposomes (Fig. 10-13) are from the 40 mg/mL sample in
the 10:1, 8:2, 8:4, and 8:6 ratios. Each sample was also
characterized using the DLS (Fig. 14) which determined the
overall size of the liposomes as well as the homogeneity.
1) Evaluation with fluorescence microscopy

II. MATERIALS AND METHODS
A. Materials
The phosphatidylcholine, cholesterol, 100% ethanol,
florescein and vitamin E were purchased from Sigma. The
glass syringes used for the ethanol injection were Hamilton
500 microliters or 100 microliters. The Lipex extruder was
purchased from Northern Lipids. The polycarbonate filters
are Whatman. The injection machine is Hamilton. The DLS
is Brookhaven and the confocal is Nikon.
B. Preparation of Liposomes
Vesicles were prepared using dry PC and CH with 10:1,
8:6, 8:4, and 8:2 PC/CH molar concentration mixtures and
were hydrated with 3mL of 100% ethanol. Liposomes were
stored at 4 ºC. The samples were alliquotted to 500 µL.
Vitamin E was added (1% by volume) to each 500 µL
sample to prevent oxidation and aggregation of the sample.
The ethanol-injection method was then used at .5, 2, 4, 6, 8,
and 10 µL per hour. A 50 or 100 mL glass syringe was used
and the 500 µL sample was then drawn up with the syringe.
The needle was loaded into a pump that regulated the
solutions ejection rate. The bezzle of the needle was placed
directly underneath the surface of a 10 mM florescein
solution in a round bottom flask. A spinner bar magnet was
put in the round bottom flask and the round bottom flask
was placed on a magnetic plate at a low stir rate. The
injected samples were dried with an argon gas to remove
any additional ethanol not encapsulated within the
liposomes. The round bottom flask remained on the

Fig. 7 Fluorescence Microscopy
a. Fluorescence images

Fig. 8 UV image of liposomes
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2) Evaluation with transmission electron microscopy
(TEM)

Fig. 13 40 mg/mL 8:2
Fig. 9 TEM Instrument

3) Evaluation with dynamic light scatterer

a. TEM images

Fig. 14 Dynamic Light Scatterer Instrument
Fig. 10 40 mg/mL 10:1
III. RESULTS

Fig. 11 40 mg/mL 8:6

Fig. 12 40 mg/mL 8:4

Based on the results of the characterization, there is a
large deviation in the size homogeneity of the 8:6 and the
10:1 ratios overall.
The 8:2 lipid to cholesterol ratio seems to be the most
stable with the smallest standard deviation in the 40mg/mL
sample (Fig. 15). In the 50mg/mL sample the 8:2 and the
8:4 ratios are the most stable (Fig. 16). The 60 mg/mL 8:4
and 8:2 ratios are currently still being characterized, but
from the data obtained the trend observed in the previous
concentrations is consistent (Fig. 17). Overall, the 8:2 ratio
of the 50 mg/mL sample has the smallest size with the least
standard deviation (Fig. 18). The injection rate analysis
indicated that the 10 mL/hr had the smallest size liposome
whereas the 4 mL/hr had the most consistent sizing
throughout the 40 and 50 mg/mL concentrations.
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IV. DISCUSSION

Fig. 15 40 mg/mL Ratio to size comparison

Fig. 16 50 mg/mL Ratio to size comparison

The ongoing project is geared towards a number of different
target studies with a goal to ensure the stability of the
liposomes is sufficient for drug delivery to humans. The
current research is being conducted in order to synthesize
and mass produce a stable liposome that is able to release
the encapsulated drug at a particular duration of time based
on the drugs specifications.
Fluorescence lifetimes would be beneficial to observe the
encapsulation efficiency of these structures. Additional
samples need to be synthesized between the 40-50 mg/mL
range to fine tune the best possible ratio as well as
observing the effects of integrating various combinations of
lipids into the liposome. Other characterization methods
may include dissolution, to monitor the rate of release, or
zeta potential, to monitor the electrical charge on the
liposomes and thus its plausibility to form aggregates.
Based on the successful results of a particular method for
synthesis of the liposome used during present research, the
efficiency and effectiveness to mass produce liposomes will
be analyzed. The capability for a particular method of
synthesis of the liposome will be analyzed for the ease to be
mass produced efficiently and cost productively.
Further studies are necessary in order to improve upon
current practices in ocular healthcare. The formation of
liposomes as a drug delivery method for ocular diseases is
the future of ocular health and will decrease many of the
current complications with current drug delivery methods.
Due to the increasing age and size of the population,
improved health and ocular care of age related diseases is
crucial. Due to this increasing elderly population and the
number of American’s being affected by these ocular
diseases, a more effective mode of drug delivery needs to be
implemented to lower the cost, decrease adverse effects,
increase patient compliance, and increase effectiveness.
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